Jiangsu Recbio Technology Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has recently received a notice of acceptance from the National Medical Products Administration to accept the application for a clinical trial of its in-house developed novel adjuvanted recombinant HPV 9-valent vaccine REC604c (the “REC604c”).

REC604c is a novel recombinant HPV 9-valent vaccine that the Company plans to develop for the male and upgraded markets. The product is upgraded on the basis of the previous generation of HPV 9-valent vaccine, equipped with an in-house developed novel adjuvant with the Company’s independent intellectual property rights. REC604c aims to achieve the purpose of reducing vaccination doses by enhancing immunogenicity and cross-protection to effectively improve product accessibility. Preclinical studies have shown that, under identical immune dosage, the immunogenicity induced by the vaccination of two doses of REC604c is generally superior to that induced by three doses of Merck Sharp & Dohme’s Gardasil®9.

HPV infection is not only the main cause of cervical cancer in females, but also can lead to condyloma acuminatum, oral cancer, male reproductive system cancer and other diseases. Published data showed that about 90% of genital warts can be attributed to HPV infection of related types. Globally, United Kingdom, Canada, and Ireland have included HPV vaccination for adolescent males in their national immunization programs, with vaccination strategies largely in line with those for females. At present, there are more than 300 million males of appropriate age in China, and the market potential is yet to be unlocked.

About Recbio

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio or the Company; stock code: 2179.HK) is an innovative vaccine company propelled by internally developed technologies. Committed to our mission of " Protect human health with best-in-class vaccines", we have cultivated a robust portfolio of vaccine products with exclusive rights, addressing the substantial unmet needs in the realm of high-impact infectious diseases. Over the course of more than two decades, Recbio has meticulously built three pioneering platforms: a novel adjuvant platform, a protein engineering platform, and an immunological evaluation platform, making us one of the few global companies capable of both developing and manufacturing the complete range of novel adjuvants.

Leveraging the close integration of our three platforms, we are consistently creating promising vaccine candidates. Fueled by these innovative platforms, the Company has forged a high-value portfolio of innovative vaccines, encompassing over ten potential blockbuster varieties. These encompass areas such as cervical cancer, shingles, RSV infection, and other prevalent high-burden diseases, and have emerged as leading products in terms of development and clinical progress in China.

Having been honed and refined over the course of a decade, Recbio is poised to reap the benefits as several products are nearing commercialization.

Forward-looking statements

This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “anticipate”, “project”, “plan”, “estimate”, “seek”, “intend”, “target”, “believe”, “potential” and “reasonably possible” or the negatives thereof or other variations thereon or comparable terminology (collectively, “forward-looking statements”), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management’s beliefs,  expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by  or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein.

Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnew.hk) or of the Company (rckt.sanmingzhi.net) for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail.

Jiangsu Recbio Technology Co., Ltd.

Investor Inquiry:

Email: ir@sanmingzhi.net

Tel: +86-0523-86818860

Media Inquiry:

Email: media@sanmingzhi.net

Tel: +86-0523-86818860

Related Links:

http://rckt.sanmingzhi.net/en/

SOURCE ：Jiangsu Recbio Technology Co., Ltd.